Advertisement
ILMN vs RVTY
Which Stock Would AI Choose? Illumina (ILMN) vs. Revvity (RVTY) Stock Comparison
Key Takeaways
- ILMN exhibits stronger year-to-date performance and one-year returns compared to RVTY.
- Illumina leads in genomics sequencing, while Revvity offers broader life sciences discovery and diagnostics tools.
- Recent partnerships and product launches have supported positive sentiment around ILMN.
- RVTY contends with weaker organic growth and margin pressures amid recent market activity.
- ILMN trades at a lower price-to-earnings (PE) ratio, suggesting relatively attractive valuation.
- Tickeron AI analysis favors ILMN for its trend consistency and catalysts.
Introduction
Illumina (ILMN) and Revvity (RVTY) are prominent players in the life sciences sector, focusing on tools essential for genomics, diagnostics, and research. This stock comparison evaluates their recent market positioning, performance drivers, and relative strengths, aiding healthcare-focused investors and traders navigating volatility in biotechnology and diagnostics. With both companies exposed to innovation in precision medicine, understanding their contrasts in growth trajectories and sentiment shifts provides valuable insights for portfolio decisions in the current environment.
ILMN Overview and Recent Performance
Illumina (ILMN) is a global leader in DNA sequencing and array-based technologies, enabling genomic analysis for research, clinical diagnostics, and oncology. In recent market activity, ILMN shares have displayed resilience, with gains in recent weeks amid broader sector pressures. Key influences include a bullish fourth-quarter 2025 earnings report, expanded partnerships such as with Labcorp for precision oncology next-generation sequencing (NGS), and initiatives in pediatric genomics with the Center for Data-Driven Discovery in Biomedicine. Analyst sentiment remains constructive, with an average price target above current levels, reflecting optimism around clinical consumables growth and software advancements like DRAGEN v4.5. These developments have bolstered investor confidence in ILMN's long-term positioning despite competitive dynamics.
RVTY Overview and Recent Performance
Revvity (RVTY), formerly PerkinElmer, delivers health sciences solutions including reagents, instruments, and software for discovery, diagnostics, and life sciences research. Recent stock behavior for RVTY has been mixed, with modest declines over recent weeks amid concerns over organic revenue growth and margins. Positive notes include product innovations like Signals BioDesign for molecular cloning and presentations at the AACR Annual Meeting 2026 showcasing cancer research tools. However, analyst caution persists due to China headwinds and a tempered 2026 growth outlook of 2-3% organically. Upcoming earnings on May 5, 2026, are in focus, with average price targets indicating potential upside but neutral ratings dominating recent updates.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots, curated from hundreds available—specifically, 25 best bots selected out of 351 total. These bots employ diverse strategies, from short-term scalping to long-term trend following, across thousands of tickers, with performance metrics highlighting win rates often exceeding 60%, average returns ranging from 10-50% annually in backtests, and varying risk profiles. Only those demonstrating superior adaptability to current market conditions earn a spot in this dynamic section, helping traders identify high-potential automated signals. Explore these bots to enhance your strategy with data-driven insights tailored to volatile environments like life sciences stocks.
Head-to-Head Comparison
Illumina (ILMN) and Revvity (RVTY) both serve the life sciences tools sector but differ in focus: ILMN specializes in high-throughput genomic sequencing, driving growth through consumables and clinical adoption, while RVTY emphasizes end-to-end discovery services and diagnostics with broader applications. Recent momentum favors ILMN, with superior one-year gains and lower PE ratio (23.58 vs. 42.14), contrasting RVTY's higher valuation amid growth slowdowns. Risk factors include regulatory hurdles for ILMN (e.g., past Grail divestiture) versus RVTY's exposure to geopolitical tensions in China. Market sentiment tilts toward ILMN on genomics tailwinds, though RVTY offers diversification trade-offs.
Tickeron AI Verdict
Tickeron’s AI currently favors ILMN over RVTY, based on stronger trend consistency, relatively lower valuation metrics, and positive catalysts like genomics partnerships and earnings momentum. While RVTY holds defensive qualities, ILMN's positioning suggests higher probability of outperformance in the near term amid sector innovation.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ILMN is a Hold and RVTY is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ILMN’s FA Score shows that 3 FA rating(s) are green whileRVTY’s FA Score has 3 green FA rating(s).
- ILMN’s FA Score: 3 green, 2 red.
- RVTY’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ILMN’s TA Score shows that 2 TA indicator(s) are bullish while RVTY’s TA Score has 5 bullish TA indicator(s).
- ILMN’s TA Score: 2 bullish, 6 bearish.
- RVTY’s TA Score: 5 bullish, 4 bearish.
Price Growth
ILMN (@Medical Specialties) experienced а +0.40% price change this week, while RVTY (@Medical Specialties) price change was -1.30% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.78%. For the same industry, the average monthly price growth was +3.12%, and the average quarterly price growth was -3.78%.
Reported Earning Dates
ILMN is expected to report earnings on Aug 12, 2026.
RVTY is expected to report earnings on Aug 03, 2026.
Industries' Descriptions
@Medical Specialties (+0.78% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| ILMN | RVTY | ILMN / RVTY | |
| Capitalization | 25B | 11.1B | 225% |
| EBITDA | 1.43B | 773M | 185% |
| Gain YTD | 25.747 | 2.509 | 1,026% |
| P/E Ratio | 29.34 | 47.62 | 62% |
| Revenue | 4.39B | 2.9B | 151% |
| Total Cash | 1.16B | 860M | 134% |
| Total Debt | 2.54B | 3.35B | 76% |
ILMN | RVTY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 85 | 24 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 75 Overvalued | 15 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 30 | 89 | |
PRICE GROWTH RATING 1..100 | 11 | 32 | |
P/E GROWTH RATING 1..100 | 7 | 33 | |
SEASONALITY SCORE 1..100 | 85 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RVTY's Valuation (15) in the Medical Specialties industry is somewhat better than the same rating for ILMN (75) in the Biotechnology industry. This means that RVTY’s stock grew somewhat faster than ILMN’s over the last 12 months.
RVTY's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as ILMN (100) in the Biotechnology industry. This means that RVTY’s stock grew similarly to ILMN’s over the last 12 months.
ILMN's SMR Rating (30) in the Biotechnology industry is somewhat better than the same rating for RVTY (89) in the Medical Specialties industry. This means that ILMN’s stock grew somewhat faster than RVTY’s over the last 12 months.
ILMN's Price Growth Rating (11) in the Biotechnology industry is in the same range as RVTY (32) in the Medical Specialties industry. This means that ILMN’s stock grew similarly to RVTY’s over the last 12 months.
ILMN's P/E Growth Rating (7) in the Biotechnology industry is in the same range as RVTY (33) in the Medical Specialties industry. This means that ILMN’s stock grew similarly to RVTY’s over the last 12 months.
| ILMN | RVTY | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 71% | 2 days ago 76% |
| Stochastic ODDS (%) | 2 days ago 84% | 2 days ago 76% |
| Momentum ODDS (%) | 2 days ago 78% | 2 days ago 70% |
| MACD ODDS (%) | 2 days ago 79% | 2 days ago 78% |
| TrendWeek ODDS (%) | 2 days ago 68% | 2 days ago 66% |
| TrendMonth ODDS (%) | 2 days ago 73% | 2 days ago 60% |
| Advances ODDS (%) | 13 days ago 70% | 8 days ago 65% |
| Declines ODDS (%) | 7 days ago 79% | 22 days ago 67% |
| BollingerBands ODDS (%) | 2 days ago 82% | 2 days ago 71% |
| Aroon ODDS (%) | 2 days ago 81% | 2 days ago 48% |
Advertisement
RVTY and
Correlation & Price change
A.I.dvisor indicates that over the last year, RVTY has been closely correlated with TMO. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if RVTY jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To RVTY | 1D Price Change % | ||
|---|---|---|---|---|
| RVTY | 100% | -0.96% | ||
| TMO - RVTY | 70% Closely correlated | -0.13% | ||
| IQV - RVTY | 65% Loosely correlated | +0.02% | ||
| A - RVTY | 65% Loosely correlated | -0.45% | ||
| CRL - RVTY | 65% Loosely correlated | -1.86% | ||
| DHR - RVTY | 64% Loosely correlated | +0.58% | ||
More | ||||